Evidence map›Paper›PMID 37533581›Full record

ArticleJID innovations : skin science from molecules to population health2023

Topical GZ21T Inhibits the Growth of Actinic Keratoses in a UVB-Induced Model of Skin Carcinogenesis.

Zachary A Bordeaux, Justin Choi, Gabriella Braun, Cole Davis, Melika Marani, Kevin Lee, Christeen Samuel, Jackson Adams, Reed Windom, Anthony Pollizzi and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JID innovations : skin science from molecules to population health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Zachary A BordeauxDepartment of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Justin ChoiDepartment of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Gabriella BraunDepartment of Anesthesiology, Duke University School of Medicine, Durham, South Carolina, USA.
Cole DavisDepartment of Anesthesiology, Duke University School of Medicine, Durham, South Carolina, USA.
Melika MaraniDepartment of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Kevin LeeDepartment of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Christeen SamuelDepartment of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Jackson AdamsDepartment of Anesthesiology, Duke University School of Medicine, Durham, South Carolina, USA.
Reed WindomDepartment of Anesthesiology, Duke University School of Medicine, Durham, South Carolina, USA.
Anthony PollizziDepartment of Anesthesiology, Duke University School of Medicine, Durham, South Carolina, USA.
Anusha KambalaDepartment of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Hannah CornmanDepartment of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Sriya V ReddyDepartment of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Weiying LuDepartment of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Olusola O OladipoDepartment of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Martin P AlphonseDepartment of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Cameron E WestGenzada Pharmaceuticals, Hutchinson, Kansas, USA.
Shawn G KwatraDepartment of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Madan M KwatraDepartment of Anesthesiology, Duke University School of Medicine, Durham, South Carolina, USA.
Johns Hopkins University · USDuke University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Actinic keratoses (AKs) are premalignant intraepidermal neoplasms that occur as a result of cumulative sun damage. AKs commonly relapse, and up to 16% undergo malignant transformation into cutaneous squamous cell carcinoma. There is a need for novel therapies that reduce the quantity and surface area of AKs as well as prevent malignant transformation to cutaneous squamous cell carcinomas. We recently showed that GZ17-6.02, an anticancer agent composed of curcumin, haramine, and isovanillin, inhibited the growth of H297.T cells. This study evaluated the efficacy of a topical formulation of GZ17-6.02, known as GZ21T, in a murine model of AK generated by exposing SKH1 mice to UVR

Identifiers

PMID37533581
PMCPMC10392087
OpenAlexW4372193903

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.